Seviteronel
Showing 1 - 6 of 6
Triple Negative Breast Cancer Trial (Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel)
Not yet recruiting
- Triple Negative Breast Cancer
- Seviteronel-D (Seivteronel in combination with dexamethasone)
- Docetaxel
- (no location specified)
Sep 21, 2021
Solid Tumor, Androgen Receptor Gene Overexpression Trial in Darlinghurst (SEVI-D (Seviteronel in combination with dexamthasone))
Terminated
- Solid Tumor
- Androgen Receptor Gene Overexpression
- SEVI-D (Seviteronel in combination with dexamthasone)
-
Darlinghurst, New South Wales, AustraliaSt Vincent's Hospital
Mar 2, 2021
Prostate Cancer Trial in United States (Seviteronel: given orally once daily in 28-day cycles)
Completed
- Prostate Cancer
- Seviteronel: given orally once daily in 28-day cycles
-
Birmingham, Alabama
- +20 more
Jan 31, 2019
Cancer of the Breast, Breast Cancer, Advanced Breast Cancer Trial in United States (Seviteronel)
Completed
- Cancer of the Breast
- +6 more
- Seviteronel
-
Birmingham, Alabama
- +35 more
Jan 31, 2019
Castration-resistant Prostate Cancer, CRPC Trial in Worldwide (Seviteronel: given orally once daily in 28 day cycles)
Completed
- Castration-resistant Prostate Cancer
- CRPC
- Seviteronel: given orally once daily in 28 day cycles
-
Homewood, Alabama
- +22 more
Jan 31, 2019
Prostate Cancer Trial run by the (VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day
Completed
- Prostate Cancer
- VT-464: given orally twice daily in 28-day cycles
- VT-464: given orally once daily in 28-day cycles
-
Bethesda, MarylandNational Institutes of Health, National Cancer Institute
May 2, 2018